HUE066069T2 - Mikafungin készítmények - Google Patents

Mikafungin készítmények

Info

Publication number
HUE066069T2
HUE066069T2 HUE17829412A HUE17829412A HUE066069T2 HU E066069 T2 HUE066069 T2 HU E066069T2 HU E17829412 A HUE17829412 A HU E17829412A HU E17829412 A HUE17829412 A HU E17829412A HU E066069 T2 HUE066069 T2 HU E066069T2
Authority
HU
Hungary
Prior art keywords
micafungin
preparations
micafungin preparations
Prior art date
Application number
HUE17829412A
Other languages
English (en)
Hungarian (hu)
Inventor
Sydney J Cope
Christine L Rebbeck
Mark J Doty
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of HUE066069T2 publication Critical patent/HUE066069T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE17829412A 2016-12-16 2017-12-15 Mikafungin készítmények HUE066069T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662435695P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
HUE066069T2 true HUE066069T2 (hu) 2024-07-28

Family

ID=60972375

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17829412A HUE066069T2 (hu) 2016-12-16 2017-12-15 Mikafungin készítmények

Country Status (11)

Country Link
US (2) US12403173B2 (https=)
EP (1) EP3554474B1 (https=)
JP (2) JP2020510619A (https=)
AU (1) AU2017376960B2 (https=)
DK (1) DK3554474T3 (https=)
ES (1) ES2972008T3 (https=)
FI (1) FI3554474T3 (https=)
HU (1) HUE066069T2 (https=)
PL (1) PL3554474T3 (https=)
PT (1) PT3554474T (https=)
WO (1) WO2018112330A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111044636A (zh) * 2019-12-30 2020-04-21 卓和药业集团有限公司 米卡芬净含量的分析方法
US20220040092A1 (en) * 2020-06-27 2022-02-10 RK Pharma Solutions LLC Ready to use injectable formulations of Micafungin Sodium
CN112710753A (zh) * 2020-12-18 2021-04-27 卓和药业集团有限公司 米卡芬净有关物质的分析方法
WO2024233925A1 (en) * 2023-05-11 2024-11-14 Hikma Pharmaceuticals Usa Inc. Stable micafungin compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
RU2165423C2 (ru) 1994-10-07 2001-04-20 Фудзисава Фармасьютикал Ко., Лтд. Полипептидное соединение, способ его получения и фармацевтическая композиция
TWI233805B (en) 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
PL1778720T3 (pl) 2004-08-18 2011-03-31 Novabiotics Ltd Antybakteryjne peptydy zawierające wzór zawierający argininę i/lub lizynę
EP2146702A2 (en) 2007-05-03 2010-01-27 NorthEastern University Methods of treating fungal infections
AU2013254940A1 (en) 2008-04-21 2014-01-16 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8183233B2 (en) 2008-05-15 2012-05-22 Baxter International Inc. Stable pharmaceutical formulations
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US20110071072A1 (en) * 2009-08-28 2011-03-24 Georgetown University, A Congressionally Chartered Institution Of Higher Education Antifungal Bone Cements
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
CN102512379B (zh) * 2011-12-16 2017-03-08 深圳市健元医药科技有限公司 一种新型棘白菌素类抗真菌药物组合物及其制备方法
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
ES2777942T3 (es) * 2014-12-31 2022-04-22 Galenicum Health S L U Composiciones farmacéuticas estables que comprenden micafungina
SG11201802832UA (en) * 2015-10-07 2018-05-30 Sumitomo Dainippon Pharma Co Ltd Pyrimidine compound
IN2015MU03858A (https=) * 2015-10-10 2015-10-23 Gufic Biosciences Ltd

Also Published As

Publication number Publication date
ES2972008T3 (es) 2024-06-10
FI3554474T3 (fi) 2024-02-21
EP3554474B1 (en) 2023-12-06
JP2024012211A (ja) 2024-01-25
US12403173B2 (en) 2025-09-02
US20180169180A1 (en) 2018-06-21
JP2020510619A (ja) 2020-04-09
PT3554474T (pt) 2024-02-12
AU2017376960A1 (en) 2019-05-23
US20250345386A1 (en) 2025-11-13
PL3554474T3 (pl) 2024-04-15
WO2018112330A1 (en) 2018-06-21
EP3554474A1 (en) 2019-10-23
AU2017376960B2 (en) 2023-12-14
DK3554474T3 (da) 2024-02-19

Similar Documents

Publication Publication Date Title
IL282304A (en) Topical pharmaceutical compositions
IL259576A (en) Compositions and methods for immunooncology
HUE053347T2 (hu) Glikopeptid-készítmények
IL254516A0 (en) Proteins specific for cd137
HRP20180501T1 (hr) Pripravci koje sadrže bakterijske sojeve
HUE058288T2 (hu) Pridopidin módosított hatóanyag-leadású készítményei
IL249313A0 (en) Improved t cell compositions
EP3317294A4 (en) STABILIZED ANTIMICROBIAL PEPTIDES
DK3723783T3 (da) Mitokondrie-målrettede peptider
IL248350B (en) Rapid-acting insulin compositions
PL3368014T3 (pl) Nowe preparaty kannabinoidów
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
IL256939B (en) Rapid-acting insulin compositions
HUE045024T2 (hu) Poliamid készítmények
EP3369741A4 (en) NOVEL PEPTIDE
HUE054096T2 (hu) Krémesítõ készítmény
HUE055231T2 (hu) Inzulint tartalmazó gyógyászati készítmények
EP3355931C0 (en) PROTEIN CONJUGATES
EP3429689A4 (en) AZELLULAR PLAZENTAPRÄPARATE
IL263714A (en) Depot formulations
HUE056166T2 (hu) Új rovargátló fehérjék
HUE055762T2 (hu) Nyújtott hatású készítmények
DK3099791T3 (da) Protein
DK3259358T3 (da) Forøget proteinekspression
HUE053624T2 (hu) Ciklosporint tartalmazó készítmények